Articles On Arc Exploration (ASX:ARX)

Aroa surges to profitability in FY25 with a NZ$4.2 million normalised EBITDA profit  Reports total revenue for full year of NZ$84.7 million, up 23% and exceeding guidance Provides total revenue guidance for FY26 of NZ$92-100 million, up 10...

Tylah Tully speaks with Aroa Biosurgery (ASX:ARX) senior medical science liaison Dr Brandon Bosque about how Aroa’s groundbreaking ECM technology, backed by 100 peer-reviewed studies, is aiming to revolutionise wound care. Bosque shares the...

ASX heath sector falls 1.3%, trailing ASX 200 up 1.1% as macro picture remains uncertain but ‘little bit better’ Soft-tissue repair company Aroa Biosurgery reconfirms FY25 reported revenue guidance of NZ$81-84 million Medical imaging softe...

Soft tissue regeneration specialist Aroa Biosurgery (ASX: ARX) has posted its second consecutive quarter of positive cash flow, in a period that also saw the company reach a key milestone with over 100 published peer reviews now validating...

AROA lifts after recording its second consecutive quarter of positive cash flows from operations Full-year FY25 guidance remains unchanged at NZ$81-$84 million in total revenue Sales of AROA’s high-margin Myriad family in March top the hig...

Aroa says the real impact from the 10% US tariff imposed on New Zealand goods will be much less than that Quarter time scores show companies are kicking with the wind Dimerix shares enter trading halt ahead of licensing deal   Kiwi wounds...

Aroa’s natural healing tech from NZ pastures is reshaping tissue repair Why Ovine ECM outperforms synthetics Aroa hits positive cash flow, with profit on the horizon   Special Report: Aroa Biosurgery’s ovine-based healing technology is ga...

Aroa achieves key milestone with seven million of its soft-tissue regeneration products used in medical procedures Company has developed a range of products using its extracellular matrix technology Aroa’s products approved in more than 50...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Brian Ward, founder and CEO at Aroa Biosurgery (ASX:ARX). Aroa was founded in 2008 by...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

Highlights Aroa Biosurgery was founded in 2008 with a focus on regenerative healing through its patented AROA ECM™ technology. Despite a drop in stock value, the company reported its first quarter of positive cash flow with a NZ$1.2m s...

The ASX200 closed up 0.57% at 8,447 points. The critical trimmed mean inflation measure was up 3.2% on an annual basis, compared to 3.6% in the September quarter. This was below the 3.3% expected by market economists for the trimmed mean...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.9% to 8,475.3 points. Four ASX shares that have failed to follow the market higher today are...

Pic via Getty ImagesRadiopharmaceuticals company Telix reports sustained revenue growth in Q4 FY24 ASX health stocks fall about 2.8% over past week Neuren’s partner Acadia submits marketing authorisation application in Europe for trofine...

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Aroa Biosurgery (ASX:ARX) VP of Medical Affairs Dr Adam Young about what drew him to the co...

ASX 200 lifts on tech rally, miners struggle Barrick Gold threatens Mali shutdown over shipping restrictions Bitcoin bounces back after recent slump   The ASX 200 index crept up 0.34% on Tuesday, thanks to a rally in tech following the Na...

Aroa’s Myriad shows success in lower limb reconstruction Study highlights Myriad’s efficacy and cost-saving benefits Myriad’s potential for $225m market validated by clinical results   Special Report: Aroa’s latest study reveals potential...

Highlights GR Engineering Services GNG shows impressive earnings growth, with a debt-free balance sheet. Polynovo PNV presents a compelling opportunity in wound care, despite recent price fluctuations. Aroa Biosurgery ARX delivers str...

Stockhead’s Sarah Hughan sits down with Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward to get the short end of the long story on the company’s latest news. The soft tissue repair products company has released its half yearly report...

If you have a higher than average tolerance for risk, then it could be worth considering a few small cap ASX stocks for a balanced portfolio. That's because the potential returns on offer at the small end of the market can be material. Thou...

Aroa Biosurgery product revenue up 27% to NZ$39.1 million on constant currency basis in H1 FY25 Myriad sales surge 45% in H1 FY25, accounting for 38% of total sales and 72% of direct sales mix during half Aroa expects to be operating cashf...

ASX health stocks fall 1.3% in past five days, while broader market is marginally up 0.7%  Neuren soars on sale of priority review voucher and $50 million share buyback Neurizon releases positive preclinical results on lead drug candidate...

Stockhead’s Sarah Hughan sits down with Aroa Biosurgery’s (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news. The company’s biomaterial ECM technology aims to improve the rate and qualit...

  The ASX fell on new expectations for rate cuts All 11 ASX sectors fell, with real estate and healthcare hit hardest MinRes and Viva Energy dropped, Prodigy Gold rose 50pc   The ASX slid by 1.66% from near record highs in a broad sell-o...

Mixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch its predictive diabetes test next year Chimeric raises $5 million – but drops its daks to do so   As the end-of-October quarterly reporting...

Aroa looks to capitalise on growing US wound-care market forecast to reach US$13 billion by 2034 Company is continuing to expand clinical evidence supporting efficacy of its ECM products Growing prevalence of chronic conditions like diabe...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode Tim chats with Brian Ward, founder and CEO at Aroa Biosurgery (ASX:ARX). Aroa was founded in 2008 by...

What is regenerative healing? Why are such healing products used? And where does AROA sits in the greater regenerative healing market? Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward joins the Stockhead TV studio to investigate thes...

What is regenerative healing? Why are such healing products used? And where does AROA sits in the greater regenerative healing market? Aroa Biosurgery (ASX:ARX) founder and CEO Dr Brian Ward joins the Stockhead TV studio to investigate thes...

Given the strong potential returns on offer at the small end of the market, it could be worth adding a few small cap ASX stocks to a balanced investment portfolio if you have a high risk tolerance. But which small caps could be top options...

ASX 200 nears 8,000 points, boosted by mining stocks Monadelphous and Baby Bunting rose; Yancoal and Dexus fell RBA considered lifting rates in August, minutes revealed   The  S&P/ASX 200 index rose by 0.2% to finish near 8,000 points...

Aroa focused on expanding clinical evidence to support use of its ECM products in soft tissue repair Aroa expands Myriad Registry, the company’s largest prospective study to date Interim results of Symphony for complex non-healing diabetic...

ASX health stocks rise 0.8% past five days as broader market lifts 3.7%  Morgans says ProMedicus ‘produced yet another record result’ with net profit of $82.8m in FY24  CSL falls on FY24 results but Morgans still bullish on ASX’s largest h...

The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors  Day one focus on new opportunities, finding the next blockbuster drug and re...

Looking for exposure to the healthcare sector in FY 2025? If you are, then check out the three ASX shares listed below. They have just been tipped as Bell Potter's top healthcare stocks to buy now: Aroa Biosurgery Ltd (ASX: ARX) Aroa Biosu...

If you're not averse to investing at the small side of the market, then it could be worth checking out Aroa Biosurgery Ltd (ASX: ARX). That's because analysts at Bell Potter believe the small cap ASX stock could rise materially from current...

AROA Biosurgery continues to expand its product line in regenerative tissue repair on back of positive clinical results Using ovine forestomach matrix, Aroa’s ECM technology offers top-tier regenerative performance at an attractive price p...

ASX health stock fall in past five days along with broader markets Sonic Healthcare cuts FY24 profit guidance, citing costs pressures and currency headwinds Aroa Biosurgery FY24 results in line with guidance with total revenue up 12% yoy...

Stockhead’s Sarah Hughan sits down with AROA Biosurgery (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news. The soft-tissue regeneration company released its FY24 financial results with...

Tech stocks surged on ASX today, offset by losses in Mining stocks Gold and copper hit all-time highs Ethereum on the rise on rumours of ETF approvals in the US   The ASX 200 closed around -0.15% lower on Tuesday, as gains in Tech stocks...

Soft tissue repair company Aroa Biosurgery FY24 revenue grows 12% yoy to NZ$69.1 million Myriad revenue up 73% to NZ$23.3 million Aroa focused on delivering positive operating cashflows in FY25 Special Report: Soft tissue repair company...

Positive net cash inflows from operations of NZ$300k, exceed Q4 breakeven expectations Strong cash receipts from customers of NZ$18 million, reflect continued increase in Myriad and OviTex/OviTex PRS sales ARX reduces quarterly cash burn b...

The ASX inched higher on Tuesday ahead of the Fed’s rates call Lithium stocks flashed green today Amazon, CocaCola, Eli Lilly to report earnings later tonight   The ASX200 edged cautiously higher by +0.35% on Tuesday on the back of a Wall...

S&P/ASX 200 Health Care (ASX: XHJ) shares are up 0.44% on Tuesday while the ASX 200 is up 0.23%. But these three ASX healthcare shares are knocking it out of the park on this otherwise lacklustre day. Here's why. Paradigm Bio...

Aroa Biosurgery focuses on transitioning operations to cashflow positive in FY25 US distribution partner TELA Bio reports strong growth to flow through to Aroa Biotech making strong progress on clinical trials and new product lines Soft...

The ASX200 has ended Friday down 0.15pc, but ends week higher Property and Healthcare gains offset by Resources losses  Small Caps led by Gold50   Wall Street hit more record highs on Thursday in New York, the Australian market on Friday,...

Stockhead’s Ashtyn Hiron sits down with AROA Biosurgery (ASX:ARX) CEO Dr. Brian Ward to get the short end of the long story on the company’s latest news. Aroa Biosurgery’s Enivo system may reduce secondary complications in mastectomies, wit...

ASX health sector up in line with broader market but some names ail after quarterly results Cochlear lifts net profit guidance for FY24 after stronger than expected first half sales revenue  CSL to report half year results next week with b...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

AROA reports 80% increase in sales of high-margin Myriad in H1 FY24 TELA Bio’s sales of OviTex and OviTex PRS increase 37% during H1 FY24 on pcp Full-year FY24 guidance has been updated   Special Report: Aroa Biosurgery released strong...